FDA
-
-
-
-
-
-
-
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
-
-
-
-
-
-
-
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
-
-
-
-
-
-
-
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
-
-
-
-
-
-
-
Corvus Hosting R&D Symposium on November 12 to Highlight COVID-19 Program and Updated Study Data Presented at SITC Annual Meeting
-
-
-
-
-
-
-
Corvus Pharma (CRVS) Announces Update on Clinical Trial of CPI-006 for Patients with COVID-19
-
-
-
-
-
-
-
Corvus Pharma (CRVS) Announces Preclinical & Initial Clinical Data from Phase 1/1b Trial of CPI-818
-
-
-
-
-
-
-
Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas
-
251,738 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All